Author:
Zhang Hanming,Gao Honglin,Zhang Yicong,Han Yikun,Lin Qing,Gong Tao,Sun Xun,Zhang Zhirong,Zhang Ling,Huang Shiqi
Publisher
Springer Science and Business Media LLC
Reference52 articles.
1. Wang, R. B.; Billone, P. S.; Mullett, W. M. Nanomedicine in action: An overview of cancer nanomedicine on the market and in clinical trials. J. Nanomater. 2013, 2013, 629681.
2. Min, Y. Z.; Caster, J. M.; Eblan, M. J.; Wang, A. Z. Clinical translation of nanomedicine. Chem. Rev. 2015, 115, 11147–11190.
3. Wilhelm, S.; Tavares, A. J.; Dai, Q.; Ohta, S.; Audet, J.; Dvorak, H. F.; Chan, W. C. W. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 2016, 1, 16014.
4. Park, K. Facing the truth about nanotechnology in drug delivery. ACS Nano 2013, 7, 7442–7447.
5. Leonard, R. C. F.; Williams, S.; Tulpule, A.; Levine, A. M.; Oliveros, S. Improving the therapeutic index of anthracycline chemotherapy: Focus on liposomal doxorubicin (Myocet™). Breast 2009, 18, 218–224.